サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：臨床診断の世界市場-2023年～2030年
市場調査レポート
商品コード
1316234

臨床診断の世界市場-2023年～2030年

Global Clinical Diagnostics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
臨床診断の世界市場-2023年～2030年
出版日: 2023年07月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界の臨床診断市場は、2022年に732億米ドルに達し、2030年には1,100億米ドルに達する好成長が予測されています。世界の臨床診断市場は、予測期間中（2023～2030年）に5.3%のCAGRを示すと予測されています。

分子診断法では、遺伝物質（DNAまたはRNA）を分析し、遺伝子変異、突然変異、または疾患に関連する特定のバイオマーカーを見つける。一般的に使用されるポリメラーゼ連鎖反応（PCR）として知られる分子技術は、特定のDNA配列を増幅して検出します。遺伝子検査、感染症検査、がんプロファイリング、遺伝性疾患の検出はすべて分子診断学が用いられています。

市場力学

活発な主要プレーヤーが予測期間中の世界臨床診断市場の成長を後押し

2023年2月、ロシュは研究開発努力をさらに強化するため、Janssen Biotech Inc.との提携を拡大し、標的治療のコンパニオン診断薬を開発すると発表しました。

新たなパートナーシップの拡大により、ロシュとヤンセンは、免疫組織化学（IHC）、デジタルパソロジー、次世代シークエンシング、ポリメラーゼ連鎖反応、イムノアッセイなど、精密医療分野におけるコンパニオン診断薬プロジェクトで協力する選択肢を増やすことになります。

技術の進歩が世界の臨床診断市場に成長機会をもたらす

2023年3月、現地で開発されたTata MD CHECKを標準化し、新たな感染率を低減するため、タタ家の新しいヘルスケア企業であるTata Medical and Diagnostics（Tata MD）は、チェンナイを拠点とするAnderson Diagnostics &Labs（ADL）と提携しました。

「Made-in-India」のTata MD CHECK診断キットは、ADLの臨床専門家との協力により、迅速なスケールアップが可能になっています。ADLはすでに、Feluda CRISPR PlatformをベースとしたDGCA承認のこの新しい診断ソリューションを使って、1万件以上のCOVID検査を成功させています。「10,000以上のサンプルをテストし、検証した結果、この技術は最先端であり、世界最高水準であると確信しています。

COVID-19の影響分析

COVID-19パンデミックは臨床診断市場に大きな影響を与えました。臨床診断の研究開発はCOVID-19のパンデミックに端を発しています。COVID-19の検出に特化した新しい診断アッセイ、技術、プラットフォームが急速に開発されました。これらの開発はパンデミックとの闘いに役立ち、臨床診断業界全体に役立つ新しいアイデアや情報を生み出しています。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争が臨床診断市場に与える影響は複雑かつ多面的です。インフラ、資源、知識が不足しているため、紛争の影響を受けた地域では新しい診断技術へのアクセスが困難になる可能性があります。分子診断や画像診断技術を含む最先端の診断技術の使用や利用が制限される可能性があり、診断サービスの正確性や完全性に影響を及ぼす可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 疾病負担の増加
    • 抑制要因
      • 厳しい規制要件
    • 機会
      • 技術の進歩
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 検査別

  • 脂質パネル
  • 肝臓パネル
  • 腎臓パネル
  • 完全血球計算
  • 電解質検査
  • 感染症検査
  • その他の検査

第10章 製品別

  • 検査機器
  • 試薬
  • その他

第11章 エンドユーザー別

  • 病院検査室
  • 診断ラボ
  • ポイントオブケア検査
  • その他

第12章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第13章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第14章 企業プロファイル

  • Abbott Laboratories
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Becton, Dickinson and Company
  • BioMerieux
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • Siemens AG
  • Hologic Inc.
  • Qiagen NV
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific

第15章 付録

目次
Product Code: CD6523

Market Overview

The global clinical diagnostics market reached US$ 73.2 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 110.0 billion by 2030. The global clinical diagnostics market is expected to exhibit a CAGR of 5.3% during the forecast period (2023-2030).

In molecular diagnostic methods, genetic material (DNA or RNA) is analyzed to find genetic variants, mutations, or particular biomarkers linked to diseases. The commonly used molecular technique known as polymerase chain reaction (PCR) amplifies and detects particular DNA sequences. Genetic testing, infectious disease testing, cancer profiling, and the detection of genetic diseases all use molecular diagnostics.

Market Dynamics

Active Major Players are Boosting the Global Clinical Diagnostics Market Growth During the Forecast Period

In February 2023, In order to further boost its research and innovation efforts, Roche stated that it had increased its partnership with Janssen Biotech Inc. to develop companion diagnostics for targeted treatments.

With the new, enlarged partnership, Roche and Janssen will have more options to work together on companion diagnostics projects in the area of precision medicine, including immunohistochemistry (IHC), digital pathology, next-generation sequencing, polymerase chain reaction, and immunoassays.

Technological Advancements Provide Global Clinical Diagnostics Market Growth Opportunities

In March 2023, In an effort to standardize the locally developed Tata MD CHECK and reduce the rate of new infections, Tata Medical and Diagnostics (Tata MD), a new healthcare company from the Tata family, has partnered with Chennai-based Anderson Diagnostics & Labs (ADL).

The "Made-in-India" Tata MD CHECK diagnostic kit can now be scaled up quickly due to the collaboration with ADL's clinical experts. ADL has already successfully completed over 10,000 COVID tests using this new, DGCA-approved, novel diagnostic solution based on the Feluda CRISPR Platform. "After testing and validating more than 10,000 samples, we believe this technology to be both cutting edge and on par with the best in the world.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the clinical diagnostics market. Clinical diagnostics research and development have been sparked by the COVID-19 pandemic. New diagnostic assays, technologies, and platforms made specifically for the detection of COVID-19 have developed quickly. These developments have aided in the fight against the pandemic and have generated new ideas and information that will help the clinical diagnostics industry as a whole.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the clinical diagnostics market is complex and multifaceted. Due to a lack of infrastructure, resources, and knowledge, access to new diagnostic technology may be difficult in conflict-affected areas. The use and accessibility of cutting-edge diagnostic techniques, including molecular diagnostics or imaging technology, may be constrained, which could have an impact on the accuracy and thoroughness of diagnostic services.

Segment Analysis

The global clinical diagnostics market is segmented based on test, product, end-user, and region.

The Lipid Panel Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The lipid panel segment accounted for the highest market stake accounting for approximately 32.3% of the clinical diagnostics market in 2022. The lipid panel measures different lipids (fats) and the characteristics that go along with them in the bloodstream. It offers significant details on a person's lipid profile and cholesterol levels, which are essential markers of cardiovascular health.

Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol are both measured as well as the overall amount of cholesterol in the blood. Healthcare providers can determine a patient's risk for cardiovascular disease based on the findings of a lipid panel test and offer medication, lifestyle changes, or other therapies as necessary.

Geographical Analysis

Asia Pacific is Expected to hold Around 25.7% Share of this Market due to Increasing Collaborations and Partnerships Among the Key Players, and Advancement in Clinical Diagnostics

Asia Pacific is expected to hold around 25.7% share of this market. For instance, in May 2023, a high-end diagnostic solutions provider called Core Diagnostics, with its headquarters in Gurugram, announced the opening of a new satellite facility in East Delhi's Hargobind Enclave. With this strategic growth, the company hopes to increase its testing capabilities and give patients and healthcare professionals better access to high-quality diagnostic services.

The satellite lab is a crucial component of Core Diagnostics' strategic expansion plan, which aims to increase the company's testing capacity and satisfy the increasing demand for quality and timely diagnostic services. By bringing superior diagnostic options closer to healthcare professionals and patients, they are able to give them the precise information they need to make prompt medical decisions.

Competitive Landscape

The major global players in the market include: Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories Inc., Danaher Corporation, Siemens AG, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, Thermo Fisher Scientific among others.

Why Purchase the Report?

  • To visualize the global clinical diagnostics market segmentation based on the test, product, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of clinical diagnostics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global clinical diagnostics market report would provide approximately 61 tables, 61 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Test
  • 3.2. Snippet by Product
  • 3.3. Snippet by End-user
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising burden of disease
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent regulatory requirements
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advancements
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Test

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
    • 9.1.2. Market Attractiveness Index, By Test
  • 9.2. Lipid Panel*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Liver Panel
  • 9.4. Renal Panel
  • 9.5. Complete Blood Count
  • 9.6. Electrolyte Testing
  • 9.7. Infectious Disease Testing
  • 9.8. Other Tests

10. By Product

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.1.2. Market Attractiveness Index, By Product
  • 10.2. Instruments*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Reagents
  • 10.4. Others

11. By End-user

    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.1.2. Market Attractiveness Index, By End-user
  • 11.2. Hospital Laboratory*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Diagnostic Laboratory
  • 11.4. Point-of-care Testing
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.6.1. U.S.
      • 12.2.6.2. Canada
      • 12.2.6.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.6.1. Germany
      • 12.3.6.2. U.K.
      • 12.3.6.3. France
      • 12.3.6.4. Italy
      • 12.3.6.5. Spain
      • 12.3.6.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.6.1. Brazil
      • 12.4.6.2. Argentina
      • 12.4.6.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Product Benchmarking
  • 13.3. Company Share Analysis
  • 13.4. Key Developments and Strategies

14. Company Profiles

  • 14.1. Abbott Laboratories*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Becton, Dickinson and Company
  • 14.3. BioMerieux
  • 14.4. Bio-Rad Laboratories Inc.
  • 14.5. Danaher Corporation
  • 14.6. Siemens AG
  • 14.7. Hologic Inc.
  • 14.8. Qiagen NV
  • 14.9. F. Hoffmann-La Roche AG
  • 14.10. Thermo Fisher Scientific

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us